ZODIAC: A Risk-based Decision Support System Did Not Significantly Improve Lipid-Lowering vs Usual Care
Key Points Maximizing lipid lowering therapy (LLTs) to optimize residual cardiovascular disease (CVD) risk after acute coronary syndrome (ACS) is usually a stepwise... Read more.
SUMMIT: Tirzepatide Decreased The Risk Of Worsening HF And CV Death in HFpEF + Obesity
Key Points SUMMIT was a multi-national trial that compared cardiovascular outcomes among patients with heart failure with preserved ejection fraction (HFpEF) and... Read more.
BPROAD: Intensive Blood Pressure Target Reduces MACE in Type 2 Diabetes
Key Points BPROAD was a randomized control trial in China that assigned nearly 13,000 participants with type 2 diabetes (T2DM) and hypertension (HTN) to either a... Read more.